Live Breaking News & Updates on Myelofibrosis Symptom Assessment

Stay updated with breaking news from Myelofibrosis symptom assessment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TP-3654 Demonstrates Favorable Tolerability, Early Clinical Activity in R/R Myelofibrosis

The oral selective PIM1 kinase inhibitor TP-3654 appeared to be well tolerated and to show early signals of spleen volume reduction, symptom improvement, and correlating cytokine reductions in patients with relapsed or refractory myelofibrosis, according to preliminary data. ....

North Carolina , United States , Duke University Medical Center , Dynamic International Prognostic Scoring System , Myelofibrosis Symptom Assessment , Pim1 Kinase Inhibitor , Tp 3654 , Phase 1 2 Tp 3654 102 Study ,

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Raajit K. Rampal, MD, PhD, presents data from the MANIFEST-2 study investigating pelabresib in combination with ruxolitinib in Janus kinase inhibitor treatment–naïve patients with myelofibrosis. ....

United States , San Diego , Raajitk Rampal , Janus Kinase Inhibitor Treatment Na , Partnership With , Total Symptom Score , North America , Manifest 2 , Manifest 2 Study , Manifest 2 Trial , Jak Inhibitor , Mash 2023 , Manifest 2 Data , Manifest 2 Results ,

Diagnosing Myelofibrosis

Patients with myelofibrosis commonly present with fatigue, weight loss, night sweats, bone pain, low blood counts, and concentration issues, with diagnosis requiring bone marrow biopsy. ....

Myelofibrosis Treatment , Enhancing Patient Quality ,

Orca-Q Showcases Early Efficacy, Acceptable Safety in Haploidentical Stem Cell Transplant Without PTCy

The high-precision cellular product Orca-Q demonstrated early signals of clinical activity as well as an acceptable safety profile for patients undergoing haploidentical stem cell transplantation without posttransplant cyclophosphamide. ....

United States , States Srour , Samera Srour , Department Of Stem Cell Transplantation , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Stem Cell Transplantation , Cancer Medicine , Cancer Center , African American , Common Terminology Criteria , Adverse Events , Orca Bio , Palebresib Plus Ruxolitinib , Jak Inhibitor Naive Myelofibrosis , Manifest 2 Trial , Ash Annual Meeting , Cpi 0610 ,

Navitoclax Plus Jakafi Improves Spleen Volume Reductions in Myelofibrosis

The recent phase 3 TRANSFORM-1 study concluded that navitoclax combined with Jakafi showed significant spleen volume reductions in patients with myelofibrosis. ....

United States , Naveen Pemmaraju , University Of Texas Md Anderson Cancer Center , Department Of Leukemia , American Society Of Hematology , Annual Meeting , Cancer Center ,